EUVIMEDEUVIMED entdecken
Metaanalyse

Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials

Joan Cid iD, Paola Charry iD, Miquel Lozano iD

Vox Sanguinis · 2024-03 · 119 (3) · 203-211

DOI: 10.1111/vox.13573 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Vox Sanguinis, online erschienen am 05.01.2024. Verfasst von Joan Cid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clí…. Hauptthemen laut MEDLINE: Platelet Transfusion, Thrombocytopenia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Clinical efficacy and safety of pathogen‐reduced platelet concentrates (PR‐PCs) concerning bleeding prevention are still debated despite conclusive real‐world data from multiple countries where PR‐PCs are transfused routinely. We performed a meta‐analysis of randomized controlled trials (RCTs) comparing the clinical efficacy and safety of conventional platelet components (PCs) and PR‐PCs prepared with the amotosalen/ultraviolet A light (INTERCEPT platelet concentrate [I‐PC]) or riboflavin/ultraviolet light (Mirasol platelet concentrate [M‐PC]) technologies, transfused in thrombocytopenic adult patients. Materials and Methods A literature search was conducted, and 10 RCTs met the criteria for inclusion in this meta‐analysis. Summary odds ratios (ORs) of clinically significant bleeding (World Health Organization [WHO] bleeding grade ≥2), severe bleeding (WHO bleeding score ≥3) and all‐cause mortality were calculated.

Results

The use of I‐PC was not associated with an increase in the OR of clinically significant bleeding when compared to non‐treated PCs (OR, 1.12; 95% CI: 0.89–1.41; p = 0.33), whereas transfusions with M‐PC showed an increase in clinically significant bleeding (OR, 1.34; 95% CI: 1.03–1.75; p = 0.03). The OR of severe bleeding did not increase with either I‐PC or M‐PC (OR 0.88; 95% CI: 0.59–1.31; p = 0.52 for I‐PC; OR 1.25; 95% CI: 0.66–2.37; p = 0.49 for M‐PC). In the case of all‐cause mortality, compared to non‐treated PC, I‐PC showed an OR of 0.61 (95% CI: 0.36–1.04; p = 0.07), and M‐PC showed an OR of 3.04 (95% CI: 0.81–11.47; p = 0.1).

Conclusion

No differences were observed concerning the clinical efficacy and safety of overall PR‐PCs when compared to non‐treated PCs. However, differences are evident when analysing platelets prepared with the two PR technologies independently.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet TransfusionThrombocytopeniaAdultHumansRandomized Controlled Trials as TopicBlood PlateletsHemorrhage

Stichwörter der Autor:innen

amotosalenmeta-analysispathogen reductionplatelet transfusionriboflavin

Autor:innen und Institutionen

  • Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Joan Cid, Paola Charry, Miquel Lozano

Zitieren

APA

Cid, J., Charry, P., & Lozano, M. (2024). Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials. Vox Sanguinis, 119(3), 203-211. https://doi.org/10.1111/vox.13573

Vancouver

Cid J, Charry P, Lozano M. Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials. Vox Sanguinis. 2024;119(3):203-211. doi:10.1111/vox.13573

BibTeX
@article{Cid2024,
  author = {Cid, Joan and Charry, Paola and Lozano, Miquel},
  title = {Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials},
  journal = {Vox Sanguinis},
  year = {2024},
  volume = {119},
  number = {3},
  pages = {203--211},
  doi = {10.1111/vox.13573}
}
Kostenlos starten →